Zobrazeno 1 - 10
of 23
pro vyhledávání: '"63"'
Autor:
Nan Zhang, Alyx B. Porter, Luke Mountjoy, Jonathan B. Ashman, Terence T. Sio, Akanksha Sharma, Maciej M. Mrugala, Naresh P. Patel, Richard J. Butterfield, Richard S. Zimmerman, Steven E. Schild, Sujay A. Vora, Helen J. Ross, Harshita Paripati, Thomas B. Daniels
Publikováno v:
American Journal of Clinical Oncology. 43:128-132
Objective Radiation therapy (RT) is the primary treatment of intracranial metastasis (ICM) from lung cancer (LC). Radiation necrosis (RN) has been reported post-RT with an incidence of 5% to 24%. We reviewed the spectrum of imaging changes in patient
Autor:
Sheila A. Conway, Aaron H. Wolfson, Jonathan C. Trent, Deukwoo Kwon, Omar Mahmoud, H. Thomas Temple, John D. Pitcher, Pasquale Benedetto, Austin R. Dosch, Gustavo Fernandez
Publikováno v:
American journal of clinical oncology. 39(5)
PURPOSE The perioperative management of primary extremity soft-tissue sarcomas (ESTS) is multidisciplinary including radiation therapy and chemotherapy (CT). The interplay between these modalities and the relative importance of each remain unclear. O
Autor:
Taing N Aung, Geetanjali R. Kamath, Sundar Jagannath, Nina A. Bickell, Jeremy Meltzer, Natalia N. Egorova, Brian Kunzel
Publikováno v:
American journal of clinical oncology. 44(12)
Enrollment in clinical trials is thought to improve survival outcomes through the trial effect. In this retrospective observational cohort study, we aimed to discern differences in survival outcomes by clinical trial enrollment and race-ethnicity.Of
Autor:
Philip J. Lupo, Dejka M. Araujo, Riddhi Patel, Robert S. Benjamin, Alexander J. Lazar, Patrick P. Lin, George L. Delclos, Andrew J. Bishop
Publikováno v:
American journal of clinical oncology. 44(7)
OBJECTIVES Synovial sarcomas (SS) arising in distal extremities are rare and have been studied using mostly case reports and small series. We aimed to evaluate clinical presentation and survival outcomes for patients with hand or foot SS. MATERIALS A
Autor:
Michael Buckstein, Aaron M. Fischman, Edward J. Kim, Michael J. King, Myron Schwartz, Umut Ozbek, Heather M. McGee, Ashley Olson, Kenneth E. Rosenzweig
Publikováno v:
American Journal of Clinical Oncology. 42:367-374
Objectives Patients with hepatocellular carcinoma (HCC) and gross vascular invasion (GVI) have poor outcomes with systemic therapy such as sorafenib. Both external beam radiation therapy (EBRT) and transarterial radioembolization (TARE) have been uti
Publikováno v:
American journal of clinical oncology. 43(8)
Objective The objective of this study was to analyze the impact of the time interval (TI) between hysterectomy and initiation of adjuvant radiation treatment (ART) on overall survival (OS) among women with early stage endometrial carcinoma (EC) using
Autor:
Juan Lin, Adel Chergui, Sanjay Goel, Haiying Cheng, Vineeth Sukrithan, Alexander Barbaro, Brian Ko
Publikováno v:
Am J Clin Oncol
OBJECTIVES Bevacizumab with chemotherapy improved overall survival (OS) in the E4599 trial in metastatic nonsquamous non-small cell lung cancer (NS-NSCLC). A meta-analysis demonstrated an OS benefit with bevacizumab only in a subset of nonwhite patie
Publikováno v:
American Journal of Clinical Oncology. 41:595-600
PURPOSE OF THE STUDY In 2003, our institution adopted triweekly carboplatin (tCb) area under the curve (AUC) 5 as an alternative to high-dose cisplatin (100 mg/m) for select patients receiving definitive concurrent chemoradiation for locally advanced
Autor:
Jiahui Zhang, Sarah E. Ferguson, Jessica L. Conway, J. Lukovic, Anthony Fyles, Kathy Han, Wei Xu, Marjan Rouzbahman, Michael Milosevic, Neesha C. Dhani, Jennifer Croke, Alexandra Rink
Publikováno v:
American journal of clinical oncology. 42(10)
OBJECTIVE The objective of this study was to determine the outcomes of patients with unresectable endometrial cancer managed with definitive or neoadjuvant radiation (RT) and/or chemotherapy. MATERIALS AND METHODS Patients with unresectable stages II
Publikováno v:
American Journal of Clinical Oncology. 38:174-178
BACKGROUND Accelerated partial breast irradiation (APBI) is a convenient alternative to whole-breast irradiation, as less overall time is needed for completion. The use of APBI outside the framework of large prospective clinical trials has markedly i